Testicular Sertoli cells exert both protective and destructive effects on syngeneic islet grafts in non-obese diabetic mice

Diabetologia

Volumn 43, Issue 4, 2000, Pages 474-480

  Korbutt, G S ^a   Suarez Pinzon, W L ^a   Power, R F ^a   Rajotte, R V ^a   Rabinovitch, A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Beta cells; Fas ligand; Islet transplantation; Neutrophils; NOD mice; Sertoli cells; Type I diabetes

Indexed keywords

CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; FAS LIGAND;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; FEMALE; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEUTROPHIL; NEWBORN; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROTECTION; SERTOLI CELL;

EID: 0034048740     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051331     Document Type: Article

References (35)

1. Barker CF, Billingham RE (1977) Immunologically privileged sites. Adv Immunol 25: 1-54
2. Selawry HP, Whittington K (1984) Extended allograft survival of islets grafted into the intra-abdominally placed testis. Diabetes 33: 405-406
3. Bellgrau D, Selawry H (1990) Cyclosporine-induced tolerance to intratesticular islet xenografts. Transplantation 50: 654-657
4. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270: 1189-1192
5. Streilein JW (1995) Unraveling immune privilege. Science 270: 1158-1159
6. French LE, Hahne M, Viard I et al. (1996) Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 133: 335-343
7. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC (1995) A role of CD95 ligand in preventing graft rejection. Nature 377: 630-632
8. Takeda Y, Gotoh M, Dono K et al. (1998) Protection of islet allografts transplanted together with Fas ligand expressing testicular allografts. Diabetologia 41: 315-321
9. Lau HT, Yu M, Fontana A, Stoeckert CJ Jr (1996) Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273: 109-112
10. Allison J, Georgiou HM, Strasser A, Vaux DL (1997) Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 94: 3943-3947
11. Kang SM, Schneider DB, Lin Z et al. (1997) Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 3: 738-743
12. Muruve DA, Nicolson AG, Manfro RC, Strom TB, Sukhatme VP, Liberman TA (1997) Adenovirus-mediated expression of Fas ligand induces hepatic apoptosis after systemic administration and apoptosis of ex vivo-infected pancreatic islet allografts and isografts. Hum Gene Ther 8: 955-963
13. Whitmore WF III, Karsh L, Gittes RF (1985) The role of germinal epithelium and spermatogenesis in the privileged survival of intratesticular grafts. J Urol 134: 782-786
14. Selawry HP, Whittington K, Forster H (1988) Prolonged intratesticular islet allograft survival in the absence of steroidogenesis. Horm Met Res 20: 562-564
15. Cameron D, Whittington K, Schultz RE, Selawry H (1990) Successful islet/abdominal testis transplantation does not require Leydig cells. Transplantation 50: 649-653
16. Selawry HP, Cameron DF (1993) Sertoli cell-enriched fractions in successful islet cell transplantation. Cell Transplant 2: 123-129
17. Korbutt GS, Elliott JF, Rajotte RV (1997) Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 46: 317-322
18. Gotoh M, Maki J, Kiyoizumi T, Satomi S, Monaco AP (1985) An improved method for isolation of mouse pancreatic islets. Transplantation 40: 437-438
19. Steinberger A, Thanki KJ, Siegal B (1974) FSH binding in rat testes during maturation and following hypophysectomy. Cellular localization of FSH receptors. In: Dufau ML, Means AR (eds) Hormone Binding and Target Cell Activation in the Testis. Plenum, New York, pp 177-192
20. Wang YM, Sullivan PM, Petrusz P, Yarbrough W, Joseph DR (1989) The androgen-binding protein gene is expressed in CD1 mouse testis. Mol Cell Endocrinol 63: 85-92
21. Alejandro R, Shienvold FL, Vaerewyck Hajek SA, Pierce M, Paul R, Mintz DH (1984) A ganglioside antigen on the rat pancreatic β cell surface identified by monoclonal antibody R2D6. J Clin Invest 74: 25-38
22. Suarez-Pinzon W, Sorensen O, Bleackley RC, Elliott JF, Rajotte RV, Rabinovitch A (1999) β-cell destruction in NOD mice correlates with Fas (CD95) expression on β-cells and proinflammatory cytokine expression in islets. Diabetes 48: 21-28
23. Jaeger C, Brendel MD, Hering BJ, Eckhard M, Bretzel RG (1997) Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts. Diabetes 46: 1907-1910
24. Seino K, Iwabuchi K, Kayagaki N et al. (1998) Chemotactic activity of soluble Fas ligand against phagocytes. J Immunol 161: 4484-4488
25. Miwa K, Asano M, Horai R, Iwakura Y, Nagata S, Suda T (1998) Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 4: 1287-1292
26. Ottonello L, Tortolina G, Amelotti M, Dallegri F (1999) Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J Immunol 162: 3601-3606
27. Hunt P, Eardley DD (1986) Suppressive effects of insulin and insulin-like growth factor I (IGF-I) on immune responses. J Immunol 136: 3994-3999
28. Wyatt CR, Law L, Magnuson JA, Griswold MD, Magnuson NS (1988) Suppression of lymphocyte proliferation by proteins secreted by cultured Sertoli cells. J Reprod Immunol 14: 27-40
29. Hedger MP, Qin J-X, Robertson DM, de Kretser DM (1990) Intragonadal regulation of immune system functions. Reprod Fertil Dev 2: 263-280
30. Selawry H, Kotb M, Herrod HG, Lu Z-N (1991) Production of a factor, or factors, suppressing IL-2 production and T cell proliferation by Sertoli cell-enriched preparations. Transplantation 52: 846-850
31. DeCesaris P, Filippini A, Cervelli C et al. (1992) Immunosuppressive molecules produced by Sertoli cells cultured in vitro: biological effects on lymphocytes. Biochem Biophys Res Commun 186: 1639-1646
32. Skinner MK (1991) Cell-cell interactions in the testis. Endocr Rev 12: 45-77
33. Turek PJ, Malkowicz SB, Tomaszewski JE, Wein AJ, Peehl D (1996) The role of the Sertoli cell in active immunosuppression in the human testis. Br J Urol 77: 891-895
34. Weiner HL (1997) Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today 18: 335-343
35. Piccirillo CA, Chang Y, Prud'homme GJ (1998) TGF-β1 somatic gene therapy prevents autoimmune disease in non-obese diabetic mice. J Immunol 161: 3950-3956